Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rituximab + mesenchymal stem cells
- Development stage
- Unknown
- Lead developer
- Southern Medical University Zhujiang Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
This combination therapy involves the co-administration of rituximab, a chimeric monoclonal antibody, and mesenchymal stem cells (MSCs) for the treatment of primary nephrotic syndrome (PNS) in patients with stage 3-4 chronic kidney disease (CKD). Rituximab functions by binding to the CD20 antigen on the surface of B-lymphocytes, leading to their depletion and a subsequent reduction in the immune-mediated inflammatory processes driving nephrotic syndrome. Mesenchymal stem cells are multipotent stromal cells known for their immunomodulatory properties and potential to promote tissue regeneration and repair in the kidneys. This therapeutic approach, investigated by Zhujiang Hospital, aims to delay disease progression and improve renal function in patients who may be resistant to conventional corticosteroid therapy or have progressed to advanced stages of renal impairment.
- Other names
- Rituximab and MSCsRituximab combined with Mesenchymal Stem Cells
02
Targets
Beyond the preview
Go deeper on rituximab + mesenchymal stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rituximab + mesenchymal stem cells.